605. Loneliness among Older Adults Living with HIV: a Study and Online Community
Session: Poster Abstract Session: HIV: Management and Clinical Outcomes
Thursday, October 4, 2018
Room: S Poster Hall
Posters
  • ID Week Poster 092418.pdf (464.7 kB)
  • Background: The population of people living with HIV (PLHIV) is aging. A new registry and online community, called Aging with Dignity, Health, Optimism and Community (ADHOC), has been launched to investigate how HIV impacts the lives of older PLHIV.

    Methods: A cross sectional analysis of ADHOC was performed on 208 PLHIV 50+ years of age. One hypothesis was that increasing age would be associated with greater loneliness. Loneliness was assessed using the UCLA Loneliness Scale (ULS-3). A score ≥ 6 was classified as lonely. The impact of aging on loneliness was analyzed by ANOVA and multiple linear regression.

    Results: ULS-3 scores ranged from 3-9 and 48.6% of subjects were classified as lonely. Significant differences were found between the 50-59, 60-65 and 65+ age groups, with older age associated with decreased loneliness (p=0.018) (Table 1). In the multiple linear regression model, these observations persisted even after controlling for gender, sexual orientation, race/ethnicity, relationship status, education, income, and number of comorbidities (Table 2). Decreases in loneliness were associated with female gender, being in a relationship, higher income, and fewer comorbidities (p<0.05).

    Conclusion: Among PLHIV over 50, loneliness is less severe in older age groups. Additional investigation is needed to better understand potential causes and to find ways to remediate loneliness among older PLHIV.

    Table 1. Comparison of ULS-3 Scores by Age

    50-59
    (n=133)

    60-65
    (n=40)

    65+
    (n=35)

    p-value1

    ULS-3 Mean±SD

    5.8±2.1

    5.1±2.0

    4.8±1.8

    0.018

    1p-value from ANOVA.

    Table 2. Multiple Linear Regression of ULS-3 Scores

    n

    %

    Coef.

    p-value

    Age

        50-59

    113

    54.3

    Ref

        60-65

    40

    19.2

    -0.80

    0.026

        65+

    35

    16.8

    -1.41

    < 0.001

    Gender

         Male

    196

    94.2

    Ref

         Female

    12

    5.8

    -2.06

    0.024

    Sexual Orientation

         Gay/Lesbian/Other

    185

    93.4

    Ref

         Heterosexual

    19

    9.3

    1.32

    0.108

    Race/Ethnicity

         White

    167

    81.1

    Ref

         Black

    13

    6.3

    -0.34

    0.600

         Hispanic/Latino

    16

    7.8

    -0.96

    0.070

         Other

    10

    4.9

    -0.99

    0.138

    Relationship Status

         Single

    95

    54.3

    Ref

         In a Relationship

    113

    45.7

    -1.43

    < 0.001

    Education

         Less than college graduate

    86

    41.4

    Ref

         College graduate (4 year)

    82

    39.4

    0.23

    0.474

         Graduate school graduate

    40

    19.2

    -0.02

    0.963

    Income

         < $50,000

    84

    44.9

    Ref

         ≥ $50,000

    103

    55.1

    -0.60

    0.049

    Comorbidities

         0-5

    77

    37.0

    Ref

         5+

    131

    63.0

    0.65

    0.026

    Mark Kane, MPH1, Peter Mazonson, MD, MBA1, Andrew Zolopa, MD2, Frank Spinelli, MD, FACP2, Pedro Eitz Ferrer, BSc MPH PHD2 and Peter Shalit, MD, PhD3, (1)Mazonson & Santas, Inc., Larkspur, CA, (2)ViiV Healthcare, Raleigh, NC, (3)Peter Shalit, MD, and Associates, Seattle, WA

    Disclosures:

    M. Kane, ViiV Healthcare: Research Contractor , Research grant and Research support . Mazonson & Santas, Inc.: Employee , Salary .

    P. Mazonson, Mazonson & Santas, Inc.: Co-Founder and Shareholder , Salary . ViiV Healthcare: Investigator and Research Contractor , Research grant and Research support .

    A. Zolopa, ViiV Healthcare: Employee , Salary .

    F. Spinelli, ViiV Healthcare: Employee , Salary .

    P. Eitz Ferrer, ViiV Healthcare: Employee , Salary .

    P. Shalit, Gilead: Consultant , Investigator and Speaker's Bureau , Consulting fee , Research support and Speaker honorarium . Viiv: Consultant and Speaker's Bureau , Consulting fee and Speaker honorarium . Janssen: Consultant , Investigator and Speaker's Bureau , Research support and Speaker honorarium . Merck: Speaker's Bureau , Speaker honorarium .

    << Previous Abstract | Next Abstract

    Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 3rd with the exception of research findings presented at the IDWeek press conferences.